However, evaluations of clinical samples have not been able to conclude if an elevated level of phosphorylated FOXO3a is associated with a poor prognosis in FLT3-ITD AML patients, but low expression of its tumor suppressive antagonist, FOXM1, does correlate with FLT3-ITD and chemoresistance in AML patients.147 All in all, further studies are necessary to elucidate the relationship between FLT3-ITD and the FOX protein family to identify markers for FLT3 inhibitor drug response. This evidence concerns the gene FLT3 and neoplasm.